Authors: Bank-Mikkelsen EM, Grimm D, Wehland M.
Abstract Summary
Aprocitentan, a novel dual endothelin receptor antagonist, shows promise for treating resistant hypertension. Studies reveal significant blood pressure reductions within 14 days at 25mg dosing, with no severe side effects. The drug works synergistically with existing antihypertensives and targets unique pathways, offering new hope for patients with hard-to-control hypertension.
Why Brain? ๐ง
Aprocitentan, a new dual endothelin receptor antagonist, shows promise for resistant hypertension by targeting a unique pathway, achieving significant blood pressure reduction within 14 days with minimal side effects.
Study Limitations:
Study limitations were not specified in the abstract.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
